Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study.

On the contrary, the subsequent decreases in the same parameters at T2 did not reach statistical significance for either anti-RBD IgG or BA.5 nAbs titers ( Table 2 ).

also in 111,027 other papers